---
title: Pivoting from enzymes to biopharmaceuticals
videoId: 58i057QXl1A
---

From: [[nikhil.kamath]] <br/> 

[[Kiran Mazumdar Shaw and her journey in biotech | Kiran Mazumdar Shaw]] made a strategic pivot with Biocon, moving from its foundational enzyme business to biopharmaceuticals, a decision that transformed the company's scale and market position <a class="yt-timestamp" data-t="01:00:53">[01:00:53]</a>.

## The Enzyme Business: Foundations and Challenges
Initially, Biocon focused on enzyme technologies, aiming to replace chemical processes with eco-friendly enzyme solutions <a class="yt-timestamp" data-t="02:28:07">[02:28:07]</a>. This approach was considered "an idea ahead of its time" as it championed sustainability and green technologies long before they became mainstream concerns <a class="yt-timestamp" data-t="02:32:04">[02:32:04]</a>. The company developed enzyme technologies for applications like effluent treatment and the paper and pulp industry <a class="yt-timestamp" data-t="02:27:07">[02:27:07]</a>.

Despite the environmental benefits, it was challenging to convince companies to adopt enzyme technologies due to their higher upfront cost compared to cheaper chemical alternatives, even though the long-term benefits of reduced waste treatment costs were clear <a class="yt-timestamp" data-t="02:50:53">[02:50:53]</a>.

## The Strategic Pivot to Biopharmaceuticals
By 2000, [[Kiran Mazumdar Shaw and her journey in biotech | Kiran Mazumdar Shaw]] recognized that the enzyme business, while successful, had a limited growth potential <a class="yt-timestamp" data-t="00:53:27">[00:53:27]</a>. She understood the concept of a business having a "shelf life" and the need for continuous reinvention to avoid reaching a "cliff" where it's too late to adapt <a class="yt-timestamp" data-t="01:10:10">[01:10:10]</a>.

The decision was made to pivot to biopharmaceuticals, a sector that promised greater scale and size <a class="yt-timestamp" data-t="00:53:30">[00:53:30]</a>. This pivot involved leveraging existing enzyme technologies and fermentation knowledge to produce pharmaceutical products <a class="yt-timestamp" data-t="00:53:40">[00:53:40]</a>. This strategy allowed the company to be "agnostic" about the end product of a technology, focusing instead on its potential applications <a class="yt-timestamp" data-t="00:53:53">[00:53:53]</a>.

In 2007, Biocon divested its enzyme business to Novozymes, its biggest competitor, to focus entirely on biopharmaceuticals <a class="yt-timestamp" data-t="01:38:39">[01:38:39]</a>. This decision was a "hard decision" but allowed the enzyme business to grow five times more under new investment <a class="yt-timestamp" data-t="01:38:47">[01:38:47]</a>.

## Growth in Biopharmaceuticals
Biopharmaceuticals are distinct from traditional pharmaceuticals as they are produced using living organisms, rather than chemical synthesis <a class="yt-timestamp" data-t="00:54:50">[00:54:50]</a>.

Biocon's foray into biopharmaceuticals began with:

*   **Statins**: The company started by making Lovastatin from fungal fermentation <a class="yt-timestamp" data-t="00:54:24">[00:54:24]</a>. Today, Biocon is the largest Statin producer globally, holding a 50% market share of Statin APIs (Active Pharmaceutical Ingredients) <a class="yt-timestamp" data-t="00:55:57">[00:55:57]</a>. In the U.S. market, Biocon holds a 40% market share in Atorvastatin and Rosuvastatin <a class="yt-timestamp" data-t="00:56:53">[00:56:53]</a>.
*   **Immunosuppressants**: Biocon also developed fermentation-based immunosuppressants like Tacrolimus, Everolimus, and Sirolimus, used by transplant patients to prevent organ rejection <a class="yt-timestamp" data-t="00:57:30">[00:57:30]</a>. The company has a 50% dominance in the raw material and finished product for these globally <a class="yt-timestamp" data-t="00:58:07">[00:58:07]</a>.
*   **Insulin**: Recognizing India's position as an "epicenter of diabetes" and the reliance on expensive imported animal insulins, Biocon initiated its insulin program in 2000 <a class="yt-timestamp" data-t="00:58:39">[00:58:39]</a>. In 2004, Biocon launched India's first recombinant human insulin, dramatically lowering prices and forcing competitor brands to follow suit, eventually phasing out animal insulins <a class="yt-timestamp" data-t="01:00:17">[01:00:17]</a>.

## Impact and Future Vision
The pivot to biopharmaceuticals was a pivotal moment, leading to Biocon's IPO in 2004 <a class="yt-timestamp" data-t="01:01:53">[01:01:53]</a>. This move propelled [[Kiran Mazumdar Shaw and her journey in biotech | Kiran Mazumdar Shaw]] into the limelight as "India's richest self-made woman" <a class="yt-timestamp" data-t="01:04:54">[01:04:54]</a>.

Biocon Biologics, a subsidiary, is now positioned to become the number one biosimilars company globally, driven by a broad portfolio and deep research pipeline <a class="yt-timestamp" data-t="01:43:57">[01:43:57]</a>. The company recently completed a $3 billion acquisition to take full commercial control of its biosimilars business, aiming to capture 100% of the value <a class="yt-timestamp" data-t="01:43:23">[01:43:23]</a>. This strategic move anticipates over $100 billion of biologic drugs coming off patent in the next decade <a class="yt-timestamp" data-t="01:44:22">[01:44:22]</a>.

[[Kiran Mazumdar Shaw and her journey in biotech | Kiran Mazumdar Shaw]] emphasizes the importance of differentiation and taking "bigger risks" as an entrepreneur to lead the way and future-proof a business <a class="yt-timestamp" data-t="01:07:05">[01:07:05]</a>. This forward-thinking approach allowed Biocon to invest in high-risk areas like biosimilars, building a competitive advantage that would be difficult for others to replicate without significantly impacting their financial performance <a class="yt-timestamp" data-t="01:07:36">[01:07:36]</a>.